Trials / Recruiting
RecruitingNCT06832839
Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 360 (estimated)
- Sponsor
- Beijing Tiantan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to comprehensively evaluate the risk factors for cognitive decline in patients with moyamoya disease, identify imaging target areas associated with cognitive damage in the brain, and explore the changes in brain structure and functional networks resulting from cerebral revascularization, as well as their relationship with cognitive improvement.
Detailed description
Moyamoya disease (MMD) is a chronic occlusive-stenosis cerebrovascular disease that characterized by the stenosis of internal carotid artery termination and the formation of net-like vessel. It is a multifactorial disease caused by genetic, inflammatory, immunological and other environmental factors. The specific pathogenesis of MMD is still unclear. The treatment modalities of revascularization and conservative management have been used in patients with MMD. Due to the long-term low perfusion state of brain tissue, most patients with MMD experience varying degrees of cognitive dysfunction, although the underlying mechanisms remain unclear. We will employ a combination of 256-lead high-density electroencephalography, multimodal magnetic resonance imaging, and biological samples to conduct a comprehensive evaluation of the risk factors associated with cognitive decline in patients with MMD. Our objectives include identifying target imaging areas indicative of cognitive damage in the brain and exploring the structural and functional changes in the cerebral network resulting from revascularization, as well as their relationship with cognitive improvement.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Revascularization | Revascularization |
Timeline
- Start date
- 2024-12-16
- Primary completion
- 2025-12-31
- Completion
- 2027-12-31
- First posted
- 2025-02-18
- Last updated
- 2025-02-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06832839. Inclusion in this directory is not an endorsement.